At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Nucleus Hybrid L24device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant
In Brief
A clinical study evaluating Nucleus Hybrid L24 for Sensorineural Hearing Loss. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acoustic-electric stimulation will be provided by the Nucleus Hybrid L24 cochlear implant system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSensorineural Hearing Loss
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedMay 2008
Primary CompletionJun 2012
Study CompletionJul 2014
TodayJul 2026
First PostedMay 16, 2008
Enrollment StartApr 1, 2008
Primary CompletionJun 1, 2012
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.1 years ago
Interventions
Nucleus Hybrid L24device
Implantation with Nucleus Hybrid L24 cochlear implant